- Home
- DECK vs INCY Comparison
DECK vs INCY Comparison
Compare DECK & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DECK
- INCY
- Stock Information
- Founded
- DECK 1973
- INCY 1991
- Country
- DECK United States
- INCY United States
- Employees
- DECK N/A
- INCY N/A
- Industry
- DECK Shoe Manufacturing
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- DECK Consumer Discretionary
- INCY Health Care
- Exchange
- DECK Nasdaq
- INCY Nasdaq
- Market Cap
- DECK 15.2B
- INCY 13.4B
- IPO Year
- DECK 1993
- INCY 1993
- Fundamental
- Price
- DECK $107.39
- INCY $68.18
- Analyst Decision
- DECK Buy
- INCY Hold
- Analyst Count
- DECK 22
- INCY 20
- Target Price
- DECK $144.56
- INCY $73.81
- AVG Volume (30 Days)
- DECK 2.9M
- INCY 1.9M
- Earning Date
- DECK 07-24-2025
- INCY 07-29-2025
- Dividend Yield
- DECK N/A
- INCY N/A
- EPS Growth
- DECK 30.25
- INCY N/A
- EPS
- DECK 6.33
- INCY 0.10
- Revenue
- DECK $4,985,612,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- DECK $10.38
- INCY $13.48
- Revenue Next Year
- DECK $7.85
- INCY $10.35
- P/E Ratio
- DECK $16.78
- INCY $702.60
- Revenue Growth
- DECK 16.27
- INCY 17.13
- 52 Week Low
- DECK $93.72
- INCY $53.56
- 52 Week High
- DECK $223.98
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- DECK 49.46
- INCY 52.32
- Support Level
- DECK $102.09
- INCY $66.83
- Resistance Level
- DECK $105.36
- INCY $70.37
- Average True Range (ATR)
- DECK 2.91
- INCY 1.93
- MACD
- DECK 0.74
- INCY -0.31
- Stochastic Oscillator
- DECK 75.43
- INCY 30.04
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.